Rare HIV-positive individuals shed light on how body could effectively handle infection

Feb 24, 2011

Although untreated HIV infection eventually results in immunodeficiency (AIDS), a small group of people infected with the virus, called elite suppressors (0.5 percent of all HIV-infected individuals), are naturally able to control infection in the absence of antiretroviral therapy, or HAART. Elite suppressors and HIV- infected individuals treated with HAART have similar levels of virus in the blood stream.

However, levels of HIV integrated into are much lower in elite suppressors compared to levels in cells from HIV-infected individuals on HAART, according to a study by University of Pennsylvania School of Medicine researchers published in PLoS Pathogens.

Elite suppressors are thought to have a more effective to HIV; specifically, more effective killer T cells, the subgroup of that kill cells infected with viruses. HIV is an RNA virus that converts its RNA genome into DNA intermediates in order to replicate. One important step in the HIV life cycle is integration - where HIV DNA inserts into the chromosomes of human helper T cells.

Cells that contain the integrated form of HIV DNA and are metabolically less active appear to be resistant to antiretroviral therapy and persist in the host, forming a latent reservoir. It will be important to understand why the HIV reservoir is lower in elite suppressors than in HIV infected individuals on HAART. To begin to address this question, it would be interesting to see if the level of integration would be lower still after placing elite suppressors on HAART.

The investigators speculate that therapeutic vaccinations aimed at generating killer similar to those in elite suppressors may be effective against the treatment resistant latent reservoir.

The cohort of elite suppressors was characterized by NIH researchers who also contributed to the study.

Explore further: Researchers look at prescription opioid abuse among young adults in NYC

More information: F Nawaz et al. The genotype of early-transmitting HIV gp120s promotes α4β7 reactivity, revealing α4β7+/CD4+ T cells as key targets in mucosal transmission. PloS Pathogens. DOI: ppat1001301 (2011).

add to favorites email to friend print save as pdf

Related Stories

A cure for HIV could be all in the 'mix'

Aug 18, 2010

Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy descri ...

Exhausted B cells fail to fight HIV

Jul 14, 2008

HIV tires out the cells that produce virus-fighting proteins known as antibodies, according to a human study that will be published online July 14 in the Journal of Experimental Medicine.

Waking up dormant HIV

Mar 16, 2009

HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains ...

Human testis harbors HIV-1 in resident immune cells

Nov 27, 2006

Researchers have demonstrated HIV replication within resident immune cells of the testis, providing an explanation for the persistence of virus in semen even after effective highly active antiretroviral therapy. The related ...

HIV measurement is questioned

Sep 27, 2006

Preliminary U.S. research indicates the HIV RNA level in untreated HIV-infected patients has little value in predicting the rate of CD4 cell count decrease.

Recommended for you

South Africa's life expectancy jumps to 61.2 years

15 hours ago

Life expectancy in AIDS-hit South Africa has shot up sharply over the past decade, thanks to life prolonging anti-retroviral (ARVs) treatment, latest estimates from the country's statistics agency showed Thursday.

User comments : 0